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Abstract
Background: The Prevention of Mother to Child Transmission of HIV (PMTCT) programme was introduced at Bindura 
Hospital in 2003. Seven additional satellite PMTCT clinics were set up in the district to increase service coverage but 
uptake of PMTCT interventions remained unsatisfactory. In this study we determined the prevalence of and factors 
associated with non-adherence to the single dose nevirapine (SD-NVP) regimen for PMTCT in Bindura town.
Methods: An analytic cross-sectional study was conducted in four health institutions in Bindura town. Participants 
were mother-baby pairs on the PMTCT programme attending routine six weeks post natal visits in the participating 
health institutions from March to July 2008. We interviewed 212 mothers using a structured questionnaire.
Results: The non-adherence rate to the maternal nevirapine dose was 30.7%, while non-adherence to the newborn 
nevirapine dose was 26.9%. The combined mother-baby pair nevirapine non-adherence was 42.9%. Non-adherence to 
the maternal dose of nevirapine was associated with lack of maternal secondary education (POR = 2.38; 95%CI: 1.05-
3.39) and multi-parity (POR = 2.66; 95%CI: 1.05-6.72), while previous maternal exposure to the PMTCT programme (POR 
= 0.22; 95%CI: 0.08-0.57) and giving the mother a NVP tablet to take home during antenatal care (POR = 0.03; 95%CI: 
0.01-0.09) were associated with improved maternal adherence to nevirapine. Non-adherence to the infant dose of 
nevirapine was associated with maternal non-disclosure of HIV results to sexual partner (POR = 2.75; 95%CI: 1.04-7.32) 
and home deliveries (POR = 48.76; 95%CI: 17.51-135.82).
Conclusions: Non-adherence to nevirapine prophylaxis for PMTCT was high in Bindura. Ensuring institutional 
deliveries, encouraging self-disclosure of HIV results by the mothers to their partners and giving HIV positive mothers 
nevirapine doses to take home early in pregnancy all play significant roles in improving adherence to PMTCT 
prophylaxis.
Background
Zimbabwe has the 4th highest rate of HIV infection in the
world, with an estimated HIV prevalence of 15.6% in
adults aged 15-49 years [1,2]. The HIV pandemic has
increasingly affected children, resulting in the reversal of
the gains that had been made in the reduction of infant
and childhood morbidity and mortality in the country.
Mother-to-child transmission of HIV (MTCT) during
pregnancy, delivery, or breastfeeding accounts for more
than 90% of the HIV infections in children below 15 years
of age [3,4]. Without interventions, 20-45% of babies born
to HIV positive women become vertically infected with
HIV [5]. Studies have shown that short-course, easy-to-
use, and affordable antiretroviral regimens can signifi-
cantly reduce MTCT of HIV . One such regimen is the
single-dose nevirapine (SD-NVP) regimen, in which the
mother ingests a dose of nevirapine (NVP) at the onset of
labor (at least 2 hrs before delivery) and another dose is
given to the baby within 72 hrs of birth [4,6-8].
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In Bindura district the PMTCT programme was started
in 2003 at Bindura Hospital. In 2004 seven additional sat-
ellite comprehensive PMTCT clinics were set up in the
district to increase the coverage of the services. Despite
these efforts, the uptake of the PMTCT interventions
remained unsatisfactory. During the period January to
May 2007 1161 mothers delivered at Bindura Hospital. Of
all these mothers, only 248 (21%) were tested for HIV
before giving birth, the rest (913) had unknown HIV sta-
tus and thus could not benefit from the PMTCT pro-
gramme. Out of the 248 mothers who were tested for
HIV before delivery, 65 (26.2%) were HIV positive. Of
these 65, only 43 (66.2%) swallowed the recommended
nevirapine doses before giving birth [9].
This then raised questions on why some pregnant
mothers took the bold step of being tested for HIV but
would not complete the recommended protocols for
them to prevent the transmission of HIV to their babies.
In Zimbabwe the SD-NVP regimen remains the recom-
mended prophylaxis for PMTCT. The government is
planning to adopt more efficacious regimens, but the
problems affecting the current SD-NVP regimen with
regard to access, uptake and adherence, may still affect
these future regimens. Identifying these problems can
assist in planning the rolling out of the new PMTCT regi-
mens. In this study we therefore set out to determine the
extent of non-adherence and to identify factors associ-
ated with the non-adherence to the SD-NVP regimen in
Bindura.
Methods
An analytic cross-sectional study was conducted in the
four health facilities that provide comprehensive PMTCT
and maternity services in Bindura town. The study popu-
lation included mothers-baby pairs registered on the
PMTCT programme and attended routine six-week post-
natal care in these health facilities. We reviewed the
health facility PMTCT registers and all registered HIV
positive mothers (and their babies) who visited these
heath facilities for postnatal care between March and July
2008 were enrolled into the study. We excluded mothers
who were on antiretroviral therapy before giving birth.
The minimum sample size was calculated as 197 moth-
ers-baby pairs, using the formulae: 
[10], assuming an error risk (zα) of 1.96, with a precision
(Δ) of ± 5% and expecting that 15.1% (p) of the mothers
would be non-adherent (as reported by Albreicht et al in
the study: Predictors of non-adherence to single dose nevi-
rapine for PMTCT in Lusaka Zambia) [11].
The mothers were interviewed using a structured ques-
tionnaire to collect information on socio-demographic,
socio-economic, socio-cultural variables, knowledge on
PMTCT as well as perceptions on health services being
provided.
Ethical approval to conduct the study was granted by
institutional review boards of the Provincial Medical
Directorate (PMD) for Mashonaland Central Province,
the Bindura Municipality Directorate of Health Services
and the Health Studies Office of the Ministry of Health.
The aim of the study was explained to all the potential
participants and written consent was obtained before the
interviews. Confidentiality was assured and maintained
throughout the study and no identifying information was
collected.
Statistical analyses were conducted using the Epi-info
statistical software (CDC-Atlanta, 2007) [12]. We first
performed descriptive analyses, looking at the extent of
non-adherence to NVP and comparing the distribution of
various characteristics among the non-adherent and
adherent mother-baby-pairs. Non-adherence was defined
as lack of ingestion or delayed ingestion of NVP by either
the mother or the baby (delayed ingestion being taken as
less than 2 hours before delivery for the mother and more
than 72 hours after birth for the baby). We then per-
formed bivariate analyses of the possible associations
between non-adherence and the variables under investi-
gation. In determining these associations prevalence odds
ratios (PORs) and their 95% confidence intervals (95%CI)
were calculated. We then conducted stratified analysis to
assess for possible effect modification (interaction) and
confounding. Lastly we performed logistic regression
analyses where all independent variables that were signif-
icant at the 0.25 level (χ2, p ≥ 0.25) in bivariate analyses
w e r e  i n c l u d e d  i n  t h e  m o d e l  [ 1 3 ] ,  t o  c o m e  u p  w i t h
adjusted PORs and 95%CIs.
Results
We interviewed 212 mothers between March and July
2008. Of the 273 PMTCT mothers who were due to
attend the six-week postnatal care in the participating
health institutions during the study period, 229 (83.9%)
attended the postpartum visit. Seventeen mothers were
excluded for failing to meet the inclusion criteria, 14 had
been on antiretroviral therapy before giving birth while
the other three indicated that they were unwilling to
respond to questions. The majority of the participating
mothers, 131 (61.8%), were aged between 21 and 30 years,
with a median age of 27.0 yrs (Q1 = 23; Q3 = 32). The
mothers were largely married (formally or informally),
np p
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Table 1: Demographic characteristics of the PMTCT mothers who participated in the study, Bindura, 2008
Characteristic Total Non-Adherent Adherent p-value
n = 212 % n = 91 (%) N = 121 (%)
Place of residence
Urban 114 (53.8) 29 (31.9) 85 (70.2) <0.001
Commercial Farming areas 41 (19.3) 27 (29.7) 14 (11.60 <0.001
Peri-urban 27 (12.7) 15 (16.5) 12 (9.9) 0.15
Communal (rural) 23 (10.8) 14 (15.4) 9 (7.4) 0.06
Mining community 7 (3.3) 6 (6.6) 1 (0.8) 0.05
Marital status
Married/co-habiting 170 (80.2) 70 (76.9) 100 (82.6) 0.30
Single 16 (7.5) 9 (7.4) 7 (7.7) 0.26
Divorced/separated 15 (7.1) 10 (11.0) 5 (4.1) 0.09
Widowed 11 (5.2) 4 (4.4) 7 (5.8) 0.76
Highest level of education attained
Up-to primary 62 (29.2) 42 (46.2) 20 (16.6) <0.001
Secondary (up-to form 4) 138 (65.1) 46 (50.6) 92 (76.0) <0.001
Secondary (Form 5 and 6) 10 (4.7) 3 (3.3) 7 (5.8) 0.40
Tertiary 2 (0.9) 0 (0) 2 (1.7) 0.22
Employment status
Formally employed 26 (12.3) 4 (4.4) 22 (18.2) 0.002
Informally employed 37 (17.5) 18 (19.8) 19 (15.7) 0.44
Not employed 149 (70.3) 69 (75.8) 80 (66.1) 0.13
170 (80.2%) and most, 150 (70.8%), had attained at least
secondary education. Of the 212 mothers only 63 (29.7%)
were gainfully employed (Table 1).
Maternal adherence to nevirapine
Out of the 212 mothers, 36 (17.0%) did not swallow nevi-
rapine doses before they gave birth. Of the 176 mothers
who swallowed the nevirapine doses, 29 (16.5%) swal-
lowed the tablets less than the recommended two hours
before they delivered. This calculates to a maternal non-
adherence rate of 65/212 (30.7%), taking into consider-
ation the timing of the single-dose nevirapine tablet
intake (Table 2).
Infant adherence to nevirapine
Out of the 212 babies, 42 (19.8%) of them did not swallow
nevirapine after birth. Of the 170 babies that swallowed
the nevirapine, 15 (8.8%) took the dose after the recom-
mended 72 hours of birth. This gives an infant nevirapine
non-adherence rate of 57/212 (26.9%), after adjusting for
the timing of the nevirapine intake (Table 2).
Mother-baby pair adherence to nevirapine
Mother-baby pairs where either the mother or the baby
or both failed to swallow nevirapine doses were 53
(25.0%), but when taking into consideration the recom-
mended time frames of swallowing the nevirapine doses,
91 (42.9%) of the mother-baby pairs were non-adherent
(Table 2).
Nevirapine accessibility and maternal adherence
Of the 212 mothers, 178 (84.0%) were given nevirapine
tablets to take home during antenatal care (ANC).
Among the 34 mothers who were not given nevirapine
tablets during ANC, 20 (58.8%) did not ingest nevirapine
before delivery and 14 (6.6%) got the nevirapine doses
during labour. Of those who got the NVP tablet during
labor, 71.4% ingested the doses less than 2 hrs before giv-
ing birth. (Figure 1)
Also of note was that among the 178 mothers who
received the nevirapine tablets during ANC, 16 (9.0%) did
not ingest the tablets before giving birth. Reasons given
for not ingesting the NVP include forgetting to take tabletKuonza et al. BMC Public Health 2010, 10:218
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(4/16), misplacing the tablet (6/16), being away from
home at onset of labour (4/16), labour progressed too fast
(2/16) and that the church advised against taking tablet
(1/16).
Place of delivery and nevirapine adherence
Comparing adherence by place of delivery, 52.7% (48/91)
of deliveries among the non-adherent group took place at
home, compared to 5.0% (6/121) of deliveries among the
adherent group. The reasons given for delivering at home
(n = 54) include the unavailability of transport (42.6%),
inability to afford paying for the transport (18.5%), clinic
was closed (14.8%)], labour progressed too fast (7.4%)]
and that the church discouraged them from going to the
hospital (3.7%).
Among the home deliveries (n = 54), most (91.7%) of
the non-adherence was of the infant NVP dose. Of the 42
infants that did not get nevirapine after birth, 76.2% were
born at home. The reasons given for the babies not get-
ting NVP included the clinic being too far (66.7%),
mother not knowing that the baby was supposed to get
NVP (11.9%), the baby was ill after birth (9.5%), the clinic
was closed (4.8%) and husband refused (4.8%).
Self-disclosure of HIV results and nevirapine adherence
More than half, 56.2%, of the mothers in the adherent
group disclosed their HIV results to their partners com-
pared to only 37.4% of the mothers in the non-adherent
group. Furthermore, 73.6% of the mothers in the adher-
ent group disclosed their HIV results to other people
(who were not their partners), compared to 57.1% of the
mothers in the adherent group.
Ability to afford paying for ANC services and nevirapine 
adherence
The majority (93.9%) of the 212 mothers were asked to
pay for antenatal services. Only 53.0% of the mothers in
the non-adherent group indicated that they could afford
paying the ANC charges, compared to 79.3% of the moth-
ers in the adherent group.
Factors associated with nevirapine non-adherence: 
bivariate analyses
Mother-baby pair non-adherence to nevirapine was asso-
ciated with residing in a farming/rural settlement, inabil-
ity to afford paying for ANC services, lack of maternal
secondary education, staying with in-laws in the same
household at the time of delivery, belonging to a religion
not allowing the use of modern medicine, maternal use of
traditional herbs during pregnancy, maternal non-disclo-
sure of HIV results to partner, making less than three
antenatal attendances, and giving birth at home. Previous
maternal exposure to PMTCT and giving the mother a
nevirapine tablet to take home during antenatal care were
associated with reduced risk of non-adherence. We also
looked at maternal employment status and multi-parity
Table 2: Prevalence of non-adherence to the maternal and newborn single doses of nevirapine in Bindura, 2008
Adherence Characteristics Frequency 95%CI
n = 212 %
Maternal nevirapine dose
Swallowed nevirapine at least 2 hrs before delivery 147 69.3 62.9-75.3
Swallowed nevirapine less than 2 hrs before delivery 29 13.7 9.5-18.8
Did not swallow nevirapine before delivery 36 17.0 12.4-22.5
Total maternal non-adherence to NVP 65 30.7 24.7-37.1
Newborn nevirapine dose
Swallowed nevirapine within 72 hrs of birth 155 73.1 66.8-78.8
Swallowed the nevirapine more than 72 hrs after birth 15 7.1 4.2-11.2
Did not swallow nevirapine after birth 42 19.8 14.9-25.6
Total newborn baby non-adherence to nevirapine 57 26.9 21.2-33.2
Combined maternal-infant nevirapine doses
Mother, baby or both took NVP within recommended time 121 57.1 50.3-63.6
Mother, baby or both took NVP outside recommended time 25 11.8 8.0-16.7
Mother, baby or both did not swallow nevirapine 66 31.1 25.2-37.6
Combined mother-baby non-adherence to NVP 91 42.9 36.4-49.7Kuonza et al. BMC Public Health 2010, 10:218
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but these were not associated with mother-baby pair
non-adherence on bivariate analysis. (Table 3).
On stratified analysis, the mother's education level
modified the association between the maternal employ-
ment status and non-adherence to NVP. Unemployed
mothers who had attained secondary education were less
associated with non-adherence (POR = 0.11, 95%CI: 0.01-
0.87) than unemployed mothers who had not attained
secondary education (POR = 3.36, 95%CI: 1.43-7.91). Dis-
tance from home to the nearest health facility also modi-
fied the association between the number of ANC sessions
attended and non-adherence to nevirapine. Mothers who
attended more than two ANC sessions and stayed within
5 km of a health facility were less likely to be non-adher-
ent (POR = 0.07, 95%CI: 0.01-0.58) than those who
attended more than two ANC sessions but resided more
than 5 km from a health facility (POR = 1.09, 95%CI:
0.29-4.12).
Factors associated with nevirapine non-adherence: logistic 
regression analyses
Lack of maternal secondary education (POR = 2.58,
95%CI: 1.11-6.00) and home deliveries (POR = 24.87,
95%CI: 8.37-73.93) were independently associated with
mother-baby pair non-adherence to nevirapine, while
p r e v i o u s  m a t e r n a l  e x p o s u r e  t o  P M T C T  ( P O R  =  0 . 1 7 ,
95%CI: 0.07-0.44) and giving the mother a nevirapine
tablet during antenatal care (POR = 0.06, 95%CI: 0.02-
0.21) independently reduced the non-adherence. (Table
4)
Further logistic regression analyses were done after
splitting the non-adherence into the maternal and infant
SD-NVP components. Maternal non-adherence to NVP
was independently associated with lack of maternal sec-
ondary education (POR = 2.38; 95%CI: 1.05-3.39) and
multi-parity (POR = 2.66; 95%CI: 1.05-6.72) while previ-
ous maternal exposure to PMTCT (POR = 0.22; 95%CI:
0.08-0.57) and giving the mother a NVP tablet to take
home during ANC (POR = 0.03; 95%CI: 0.01-0.09) inde-
pendently reduced maternal non-adherence. Infant non-
adherence to nevirapine was associated with maternal
non-disclosure of HIV results to sexual partner (POR =
2.75; 95%CI: 1.04-7.32) home deliveries (POR = 48.76;
95%CI: 17.51-135.82). (Table 4)
Availability of resources for PMTCT
Drugs for PMTCT prophylaxis (nevirapine tablets and
nevirapine suspension) and rapid HIV testing kits were
available in all the four participating health facilities
throughout the study period. Each of the four health cen-
tres had at least two nurses trained on PMTCT working
in the PMTCT sections, though there was a general
shortages of nurses in the institutions.
Discussion
Non-adherence to the SD-NVP regimen was high in Bin-
dura, compared to some previous studies [11,14] though
it was comparable to one Kenyan study where they found
non-adherence rates of up-to 55% [15]. The high non-
adherence in our study was probably because our defini-
tion of non-adherence included the ingestion of a NVP
dose outside the recommended times. Some previous
studies defined non-adherence only as the failure to
ingest NVP [11,14]. Successful PMTCT prophylaxis also
depends on the timing of the NVP ingestion. If the mater-
nal NVP dose is ingested less than 2 hours before delivery
the concentration in the blood may not reach enough
therapeutic levels before giving birth and if the infant
NVP dose is swallowed after 72 hours of birth the baby
may not get the full benefits of the drug [16,17]. It is
therefore important to consider the timing of the NVP
intake when looking at adherence to the NVP regimen.
While most previous studies looked at adherence only to
the maternal NVP dose, our study defined non adherence
looking at both the maternal and the infant doses of NVP.
The infant dose of NVP is equally important for the regi-
men to be effective and thus the prophylaxis cannot be
considered complete without administration of the infant
NVP dose. A few studies have also looked at both mater-
nal and infant adherence to PMTCT prophylaxis [11,18].
Of concern was that most babies born at home did not
receive their NVP doses or received them too late. We
attributed this to cultural practices in the studied popula-
tion; newborn babies are confined within the house until
the shedding of the umbilical cord stump, which usually
takes about a week. The low self-disclosure of HIV results
by the HIV positive mother also makes it difficult for her
to convince the partner or the relatives of the need to take
Figure 1 The patterns of maternal nevirapine non-adherence in 
relation to the accessibity of the maternal dose of nevirapine, 
Bindura, 2008. The flow diagram shows the adherence patterns of the 
mothers with reference to whether or not they received the nevirapine 
tablet during antenatal care (before the onset of labour).
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Table 3: Factors associated with non-adherence to the nevirapine prophylaxis in Bindura: Bivariate analyses
Variable SD-NVP Adherence status POR 95% CI
Non-Adherent Adherent
n = 91 (%) n = 121 (%)
Resides in a farming or rural settlement 41 (45.1) 23 (19.0) 3.49 1.89-6.45
Unable to afford paying for health services 39 (42.9) 24 (19.8) 3.40 1.82-6.33
No maternal secondary education 42 (46.2) 20 (16.5) 4.33 2.30-8.15
Stays with in-laws in same household 20 (22.0) 14 (11.6) 2.15 1.02-4.54
Belongs to a restrictive religion 31 (34.1) 23 (19.0) 2.20 1.17-4.12
Used herbal medicine during pregnancy 29 (31.9) 12 (9.9) 4.25 2.02-8.92
Did not disclose HIV status to partner 57 (62.6) 53 (43.8) 2.15 1.23-3.75
Attended less than three ANC sessions 14 (15.4) 5 (4.1) 4.22 1.46-12.19
Delivered at home 48 (52.7) 6 (5.0) 21.40 8.54-53.59
Exposed to PMTCT in previous pregnancy 17 (18.7) 56 (46.3) 0.27 0.14-0.50
Received a nevirapine tablet during ANC 61 (67.0) 117 (96.7) 0.07 0.02-0.20
Mother not gainfully employed 68 (74.7) 80 (66.1) 1.16 0.84-3.10
Multi-parity (4th child and above) 25 (27.5) 21 (17.4) 1.80 0.93-3.48
the baby to the clinic for the NVP dose before the week
lapses. Other studies have also reported an association
between home deliveries and babies missing their NVP
doses [19,20].
Non-adherence to the maternal dose of NVP was more
than twice higher among mothers who had no secondary
education. Maternal education enhances communication
between the mother and healthcare providers and also
improves retention of provided information, leading to
better implementation of recommended interventions.
Education also empowers the woman to have autonomy
in making important decisions without relying on other
people. Similar findings have been reported in previous
studies [11,19].
NVP non-adherence was four times higher among
mothers who attended less than three antenatal sessions
during pregnancy. Attending more ANC sessions offers
more opportunities for healthcare providers to reinforce
issues such as the importance of taking the NVP at the
recommended times, the importance of delivering insti-
tutionally, the need to take the baby to the clinic in the
event that birth takes place at home, and others which
have a bearing on adherence to NVP prophylaxis. Investi-
gators in a similar study in Rwanda also found an associa-
tion between non-adherence to PMTCT protocols and
attending few ANC sessions [19].
Maternal non-adherence to NVP was almost three
times higher in multi-parous mothers. Such women usu-
ally experience precipitate labour pains which are often
detected late, resulting in delayed ingestion of prophylac-
tic doses. Similar findings were reported in Zambia [11].
Giving the mothers NVP tablets to take home during
ANC improved adherence. The woman who gets NVP in
advance can ingest the pill even if she gives birth at home.
Also among the mothers who deliver in health institu-
tions, those who get the NVP in advance are more likely
to ingest the tablets on time than those who wait to take
the NVP doses on arrival to the hospital labour ward.
There are some limitations in this study that are worth
noting. Our measurement of non-adherence relied on
accurate reporting by the mother and could have been
affected by recall bias since some of the mothers deliv-
ered more than 6 weeks prior to the interviews, and their
records did not indicate the timing of NVP ingestion. It is
also possible that some women who failed to ingest their
NVP doses could have falsely claimed otherwise, making
the results to underestimate the prevalence of non-adher-
ence. Lastly, this study only looked at mothers who
reported for postnatal care, there is the possibility that
those women who did not attend postnatal care could be
more non-adherent, possibly underestimating the true
non-adherence.
Conclusions
Non-adherence to the SD-NVP regimen was high in Bin-
dura. Giving the HIV positive mother a nevirapine dose
to take home during antenatal care, giving birth in health
institutions and self disclosure of HIV results by the
mother to the partner were associated with reduced nevi-Kuonza et al. BMC Public Health 2010, 10:218
http://www.biomedcentral.com/1471-2458/10/218
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rapine non-adherence. Nurses working in the PMTCT
clinics should ensure that HIV positive mothers are given
nevirapine tablets at first contact, regardless of the stage
of the pregnancy. Health promotion should be intensified
at the community level to encourage ANC attendance
and institutional deliveries. The government should con-
sider adopting a policy of dispensing infant NVP doses
during ANC, as is done for the maternal dose, and the
possibility of incorporating traditional birth attendants
into the PMTCT programme, so as to increase access to
the ARV prophylaxis.
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